436 related articles for article (PubMed ID: 22950533)
1. Opioid-induced bowel dysfunction: pathophysiology and management.
Brock C; Olesen SS; Olesen AE; Frøkjaer JB; Andresen T; Drewes AM
Drugs; 2012 Oct; 72(14):1847-65. PubMed ID: 22950533
[TBL] [Abstract][Full Text] [Related]
2. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group.
Drewes AM; Munkholm P; Simrén M; Breivik H; Kongsgaard UE; Hatlebakk JG; Agreus L; Friedrichsen M; Christrup LL
Scand J Pain; 2016 Apr; 11():111-122. PubMed ID: 28850449
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction.
Leppert W
Drug Des Devel Ther; 2015; 9():2215-31. PubMed ID: 25931815
[TBL] [Abstract][Full Text] [Related]
4. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
Holder RM; Rhee D
Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study.
Abramowitz L; Béziaud N; Labreze L; Giardina V; Caussé C; Chuberre B; Allaert FA; Perrot S
J Med Econ; 2013 Dec; 16(12):1423-33. PubMed ID: 24102123
[TBL] [Abstract][Full Text] [Related]
6. Effect of a fixed-dose opioid agonist/antagonist on constipation in patients on long-term opioids for non-malignant pain unable to tolerate laxatives.
Mehta V; Alaward S; Kuravinakop S; Nikolic S
Pain Physician; 2014; 17(5):415-24. PubMed ID: 25247899
[TBL] [Abstract][Full Text] [Related]
7. Incidence, prevalence, and management of opioid bowel dysfunction.
Pappagallo M
Am J Surg; 2001 Nov; 182(5A Suppl):11S-18S. PubMed ID: 11755892
[TBL] [Abstract][Full Text] [Related]
8. The impact of naloxegol on anal sphincter function - Using a human experimental model of opioid-induced bowel dysfunction.
Grønlund D; Poulsen JL; Krogh K; Brock C; Liao D; Gregersen H; Drewes AM; Olesen AE
Eur J Pharm Sci; 2018 May; 117():187-192. PubMed ID: 29432808
[TBL] [Abstract][Full Text] [Related]
9. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain.
Webster L; Jansen JP; Peppin J; Lasko B; Irving G; Morlion B; Snidow J; Pierce A; Mortensen E; Kleoudis C; Carter E
Pain; 2008 Jul; 137(2):428-440. PubMed ID: 18164818
[TBL] [Abstract][Full Text] [Related]
10. The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation.
Leppert W; Zajaczkowska R; Wordliczek J
Expert Opin Pharmacother; 2019 Apr; 20(5):511-522. PubMed ID: 30625013
[TBL] [Abstract][Full Text] [Related]
11. Opioid induced bowel disease: a twenty-first century physicians' dilemma. Considering pathophysiology and treatment strategies.
Sharma A; Jamal MM
Curr Gastroenterol Rep; 2013 Jul; 15(7):334. PubMed ID: 23836088
[TBL] [Abstract][Full Text] [Related]
12. A review of the potential role of methylnaltrexone in opioid bowel dysfunction.
Foss JF
Am J Surg; 2001 Nov; 182(5A Suppl):19S-26S. PubMed ID: 11755893
[TBL] [Abstract][Full Text] [Related]
13. Opioid-induced bowel dysfunction.
Ketwaroo GA; Cheng V; Lembo A
Curr Gastroenterol Rep; 2013 Sep; 15(9):344. PubMed ID: 23900996
[TBL] [Abstract][Full Text] [Related]
14. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
Kurz A; Sessler DI
Drugs; 2003; 63(7):649-71. PubMed ID: 12656645
[TBL] [Abstract][Full Text] [Related]
15. Opioid-induced bowel dysfunction in healthy volunteers assessed with questionnaires and MRI.
Nilsson M; Poulsen JL; Brock C; Sandberg TH; Gram M; Frøkjær JB; Krogh K; Drewes AM
Eur J Gastroenterol Hepatol; 2016 May; 28(5):514-24. PubMed ID: 26795566
[TBL] [Abstract][Full Text] [Related]
16. Validated tools for evaluating opioid-induced bowel dysfunction.
Olesen AE; Drewes AM
Adv Ther; 2011 Apr; 28(4):279-94. PubMed ID: 21437762
[TBL] [Abstract][Full Text] [Related]
17. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans.
Holzer P
Neurosci Lett; 2004 May; 361(1-3):192-5. PubMed ID: 15135926
[TBL] [Abstract][Full Text] [Related]
18. Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal?
Holzer P
Curr Pharm Des; 2012; 18(37):6010-20. PubMed ID: 22747544
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
Irving G; Pénzes J; Ramjattan B; Cousins M; Rauck R; Spierings EL; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
J Pain; 2011 Feb; 12(2):175-84. PubMed ID: 21292168
[TBL] [Abstract][Full Text] [Related]
20. Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness.
Diego L; Atayee R; Helmons P; von Gunten CF
Expert Rev Gastroenterol Hepatol; 2009 Oct; 3(5):473-85. PubMed ID: 19817669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
